Abiomed's heart pump gets EU nod

Thu Apr 12, 2012 6:30pm IST

A zoomed picture shows two surgeons performing an operation to implant an artificial heart valve in the operating room of a Berlin hospital August 15, 2003. REUTERS/Fabrizio Bensch

A zoomed picture shows two surgeons performing an operation to implant an artificial heart valve in the operating room of a Berlin hospital August 15, 2003.

Credit: Reuters/Fabrizio Bensch

Related Topics

Stocks

   

(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.

The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.

The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.

Impella cVAD is still not approved in the United States.

Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.

(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Medical Update

Reuters Showcase

A Little Help

A Little Help

Researchers "buzz" the brain to speed up learning.  Video 

Disease Outbreak

Disease Outbreak

WHO says West African Ebola outbreak to last 2-4 months.  Full Article 

Healthy Food

Healthy Food

For teen girls, fruits and veggies linked to lower risk of breast condition.  Full Article 

Milk Effect

Milk Effect

Drinking milk may slow women's knee arthritis.  Full Article 

Rising Obesity

Rising Obesity

U.S. childhood obesity rates have increased since 1999: study.  Full Article 

Quality Check

Quality Check

Just because it's sweet and sticky doesn't mean it's 'honey': FDA.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.   Full Coverage